Shen Lian Biomedical

Name

Shen Lian Biomedical

Legal name

申联生物医药（上海）股份有限公司

Website

https://shenlianbiotech.com.cn

Company type

Public

Founded year

2001

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Veterinary Biological Products / Animal Health Vaccines and Diagnostics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAMAKAB

Livestock Vaccines (Cattle, Swine, Sheep & Goats)

Healthcare & Life Sciences/Veterinary & Animal Health/Animal Vaccines

SECONDARYHLAMAKAH

Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA)

Healthcare & Life Sciences/Veterinary & Animal Health/Animal Vaccines

SECONDARYHLAMAKAM

Vaccine R&D, Clinical/Field Trials & Regulatory Affairs

Healthcare & Life Sciences/Veterinary & Animal Health/Animal Vaccines

SECONDARYHLAMAKAA

Companion Animal Vaccines (Dogs & Cats)

Healthcare & Life Sciences/Veterinary & Animal Health/Animal Vaccines

SECONDARYAFAEANAK

Veterinary Pharmacy, Vaccine & Biologics Services

Agriculture & Food Production/Animal Production & Aquaculture/Animal Health & Veterinary Services

Keywords

• Veterinary biological products
• Animal vaccines
• Veterinary diagnostics
• Synthetic peptide vaccines
• MRNA veterinary vaccines

Headquarters

HQ city

Minhang

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Infrastructure, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. 兽用生物制品销售 (Veterinary Biological Products): The company's primary revenue stream from developing, manufacturing, and selling veterinary vaccines (synthetic peptide, inactivated, subunit/VLP, live vaccines) and diagnostic reagents for pigs, ruminants, and companion animals. Revenue is generated through direct sales to large livestock farms and through distribution channels across China.
2. 技术服务和CDMO (Technical Services & Contract Development): The company provides end-to-end R&D and manufacturing services through its technology platforms including mRNA, synthetic peptide, and gene engineering, serving external clients for nucleic acid vaccine development, peptide drug development, and diagnostic product customization.
3. 创新药License-out (Human Pharmaceutical Licensing Revenue): Through subsidiary Genesis Life Sciences (世之源), the company participates in human innovative drug development with potential out-licensing revenue. UB-221 was licensed to Cue Biopharma for up to $691.5 million total consideration including upfront, milestones, and royalties.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Shen Lian Biomedical develops, manufactures, and commercializes veterinary biological products — including synthetic peptide vaccines, inactivated vaccines, genetically engineered subunit/VLP vaccines, mRNA/circular mRNA vaccines, and in vitro diagnostic reagents — for pigs, ruminants (cattle, sheep), and companion animals. The company operates two GMP-certified production bases in Shanghai and Lanzhou, and is designated by the Ministry of Agriculture and Rural Affairs as a foot-and-mouth disease vaccine manufacturer. Following its 2026 acquisition of controlling stake in Genesis Life Sciences, it has also entered human-use innovative monoclonal antibody drug development.

Differentiator

Problem solved

Functional benefit

Brands

• 联圆净: Porcine circovirus type 2 subunit vaccine (recombinant baculovirus OKM strain)
• 泰吉联
• 泰祥联
• 联瘟净
• 联结净
• 传联清
• 泰瑞联
• 世之源 (Genesis Life Sciences)

Products and services

• 联圆净 (Lian Yuan Jing) - Porcine Circovirus Type 2 Subunit Vaccine (Recombinant Baculovirus OKM Strain) Vaccine for prevention of porcine circovirus type 2 (PCV2) infection in pigs, utilizing a recombinant baculovirus expression system. Targeted at large-scale pig farms for herd health management.
• 泰吉联 (Tai Ji Lian) - Porcine FMD Type O and A Bivalent Inactivated Vaccine Inactivated vaccine for prevention of foot-and-mouth disease (FMD) type O and A in pigs, using reverse genetics strains Re-O/MYA98/JSCZ/2013 and Re-A/WH/09. Designated by the Ministry of Agriculture for national FMD prevention.
• 泰祥联 (Tai Xiang Lian) - Porcine FMD Type O and A Bivalent Synthetic Peptide Vaccine Synthetic peptide vaccine for prevention of foot-and-mouth disease type O and A in pigs, combining multiple antigenic peptides for broad protection. First-in-class commercialization of synthetic peptide technology in China for veterinary vaccines.
• Porcine FMD Type O Synthetic Peptide Vaccine (Polypeptides 2600+2700+2800) Synthetic peptide vaccine for prevention of foot-and-mouth disease type O in pigs, combining polypeptides 2600, 2700, and 2800 for multi-epitope protection.
• 传联清 (Chuan Lian Qing) - Swine Streptococcosis and Porcine Pleuropneumonia Bivalent Inactivated Vaccine Bivalent inactivated vaccine for prevention of swine streptococcosis (Streptococcus suis type 2) and porcine infectious pleuropneumonia (Actinobacillus pleuropneumoniae type 1) in pigs. Targets major pathogenic serotypes prevalent in China.
• 联瘟净 (Lian Wen Jing) - Classical Swine Fever Gene Engineering Subunit Vaccine (CHO-133D) Gene engineering subunit vaccine for prevention of classical swine fever (CSF) in pigs, using CHO cell line stably expressing E2 protein with DIVA capability (distinguishing vaccine immune from wild-type infection). China's first CHO-expressed CSF E2 vaccine.
• 联结净 (Lian Jie Jing) - Bovine Lumpy Skin Disease Inactivated Vaccine (Goat Pox Virus AV41 Strain, Suspension Culture) Inactivated vaccine using goat pox virus AV41 strain for prevention of bovine lumpy skin disease, manufactured via suspension culture. Co-developed with Chinese Academy of Agricultural Sciences Lanzhou Veterinary Research Institute.
• 泰瑞联 (Tai Rui Lian) - FMD Type O and A Bivalent Inactivated Vaccine for Cattle Inactivated vaccine for prevention of foot-and-mouth disease type O and A in cattle and other ruminants, using reverse genetics technology for seed virus modification.
• Porcine Senecavirus A ELISA Antibody Detection Kit ELISA diagnostic kit for detection of antibodies against porcine Senecavirus A, used in veterinary laboratories and pig farms for disease surveillance.
• Porcine Pseudorabies Virus gB Competitive ELISA Antibody Detection Kit Competitive ELISA kit for detection of antibodies against pseudorabies virus gB protein in pigs, providing differentiation of vaccinated from naturally infected animals (DIVA).
• Porcine FMD Virus VP1 Structural Protein Antibody ELISA Diagnostic Kit ELISA diagnostic kit for detection of antibodies against VP1 structural protein of foot-and-mouth disease virus in pigs. Used for vaccine efficacy monitoring and disease surveillance.
• African Swine Fever Virus Fluorescent PCR Nucleic Acid Detection Kit Fluorescent PCR-based diagnostic kit for detection of African swine fever virus (ASFV) nucleic acid in pig samples. Used for ASF surveillance and outbreak diagnosis in pig farms and veterinary labs.
• Bovine and Ovine FMD Virus VP1 Structural Protein Antibody ELISA Diagnostic Kit ELISA diagnostic kit for detection of antibodies against VP1 structural protein of foot-and-mouth disease virus in cattle and sheep. Used for vaccine efficacy monitoring and disease surveillance in ruminants.
• Long-Acting Canine Interferon (长效犬干扰素) Long-acting interferon therapeutic biological product for use in companion animals (dogs), developed for the pet healthcare market. Targeted at veterinary clinics and pet hospitals.
• Pet mRNA Vaccine (RKC0042024) (宠物mRNA疫苗) mRNA vaccine designed for companion animals (pets), part of the company's emerging pet biological product portfolio leveraging its proprietary circular mRNA technology platform.
• GnRH Nucleic Acid Vaccine (一种GnRH核酸疫苗) GnRH nucleic acid vaccine for pet immunosterilization applications, the first domestic patent granted for GnRH target nucleic acid vaccine technology. Developed using the company's self-developed mRNA platform with optimized GnRH antigen design.
• 联痢清 (Lian Li Qing) - Piglet Paratyphoid Live Vaccine Live vaccine for prevention of piglet paratyphoid (Salmonella infection), the company's first approved live vaccine product. Marks an important breakthrough in the live vaccine field for Shen Lian.

Quantifiable outcome

• Antigen degradation rate less than 10% within validity period (i-MolSta technology)
• +6 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

15 partnerships are on record, tiered core, minor and moderate.

• Cue BiopharmacoreOEM/ Whitelabel/ Licensing Partner · 6 May 2026Genesis subsidiary's UB-221 (Ascendant-221) out-licensed to Cue Biopharma for global rights (excluding mainland China, Hong Kong, Macau, Taiwan). Deal worth up to $691.5M ($15M upfront + up to $676.5M milestones + royalties). Cue plans to initiate global Phase 2b trials for food allergy.
• 扬州世之源生物科技有限责任公司 (Yangzhou Genesis Life Sciences Co., Ltd.)coreStrategic or Co-development Partner · 1 October 2025Shen Lian acquired controlling stake (51%) in Genesis for ~CNY 237 million in Feb 2026. Genesis develops human monoclonal antibody drugs (UB-421, UB-221, UB-621). The acquisition marks Shen Lian's entry into dual business of human pharmaceuticals and animal health.
• 摩尼肽 (Monipeptide)minorStrategic or Co-development Partner · 1 October 2025Co-shareholder in Genesis Life Sciences, part of the joint management and resource integration partnership to enable full-chain deep collaboration from R&D to production.
• 中国农业科学院兰州兽医研究所 (Chinese Academy of Agricultural Sciences Lanzhou Veterinary Research Institute)coreStrategic or Co-development Partner · 1 August 2025Signed cooperation agreements to jointly develop two multivalent vaccines: (1) Swine FMD Type O/A + Classical Swine Fever + Pseudorabies Trivalent Vaccine, and (2) Bovine FMD Type O/A + BVD/MD + IBR Trivalent Vaccine. Leverages Lanzhou Institute's seed virus research with Shenlian's industrialization platform.
• 上海建毅腾创生物医药科技有限公司 (Shanghai Tengchuang Biotechnology Co., Ltd.)moderateStrategic or Co-development Partner · 1 August 2024Strategic partnership and investment agreement in pet biological products. Shenlian will leverage its diversified biotech platform and production capacity while Tengchuang provides expertise in pet drug clinical needs and drug target analysis. Cooperation covers pet antibody drugs, vaccines, diagnostic reagents, and peptide formulations.
• 中国农业科学院上海兽医研究所 (Chinese Academy of Agricultural Sciences Shanghai Veterinary Research Institute)coreStrategic or Co-development Partner · 13 October 2023Signed co-development contract for African swine fever PRRSV recombinant live vector vaccine. Project selected for National Natural Science Foundation of China 2021 ASF Special Project and 14th Five-Year National Key R&D Program. Currently at laboratory research stage with successful transgenic safety 'intermediate test' evaluation.
• 苏州科锐迈德生物医药科技有限公司 (Suzhou Cuirui Maide Biomedical Technology Co., Ltd.)coreStrategic or Co-development Partner · 18 April 2023Signed animal mRNA vaccine and drug cooperation project. Cuirui Maide provides circular mRNA platform technology to Shen Lian for veterinary biologicals development. Plan to prioritize development of PRRSV and ASF vaccines, expanding to other economic and companion animal products.
• 福州欣牧生物科技有限公司 (Fuzhou Xinmu Biotechnology Co., Ltd.)minorChannel Partner/ Reseller/ DistributorRegional distributor and co-organizer of the company's pig disease prevention empowerment conference in Fuzhou. Represents the company's channel distribution network in specific provinces.
• 中国农业科学院哈尔滨兽医研究所 (CAAS Harbin Veterinary Research Institute)moderateStrategic or Co-development PartnerEstablished R&D collaboration with Harbin Veterinary Research Institute in veterinary vaccine development, part of the company's multi-institutional academic partnership network.
• 上海交通大学 (Shanghai Jiao Tong University)moderateStrategic or Co-development PartnerAcademic partnership for joint research and talent development in veterinary biologicals. Part of the company's broader industry-university-research collaboration network.
• 河南农业大学 (Henan Agricultural University)moderateStrategic or Co-development PartnerAcademic partnership for joint research in veterinary vaccine development, part of the multi-institutional research network.
• 南京农业大学 (Nanjing Agricultural University)moderateStrategic or Co-development PartnerAcademic partnership for veterinary biologicals research, part of the university's-industry collaboration ecosystem.
• 农业农村部动物免疫学重点实验室 (Key Laboratory of Animal Immunology, Ministry of Agriculture)coreStrategic or Co-development PartnerEstablished deep industry-university-research integration mechanism with the Key Laboratory of Animal Immunology, jointly advancing innovation in animal vaccine development.
• 扬州大学 (Yangzhou University) - National Dairy Cattle Industry Technology SystemmoderateStrategic or Co-development PartnerCo-established dairy cow health breeding demonstration base with the Yangzhou University team of the National Dairy Cattle Industry Technology System. Focused on dairy cattle biological product validation, farm technical services, and disease prevention research.
• 张改平院士 (Academician Zhang Gaiping)moderateStrategic or Co-development PartnerAcademician of Chinese Academy of Engineering, former President of Henan Agricultural University. Academic expert advisory engagement including discussions on ASF vaccine R&D and mRNA vaccine development. Provided guidance on company strategy and technical direction.

Scale indicators8 records

Recent moves10 records

Expansion highlights6 records

Broad incumbents

• MSD Animal Health: Animal health division of Merck; global top-three animal health player with a comprehensive livestock and companion animal vaccine portfolio. Comparable in technology diversity and species coverage; competes with Shen Lian particularly in the mRNA veterinary vaccine category globally.
• Zoetis: Global animal health leader and largest pure-play animal health company worldwide. Comparable in technology platform breadth (mRNA, recombinant, inactivated) and species coverage (livestock + companion animals). Represents the long-term benchmark for a veterinary biologics-focused platform strategy.
• Boehringer Ingelheim Animal Health: Top-three global animal health player with a strong veterinary vaccines portfolio including FMD and swine vaccines. Competes with Shen Lian in multinational livestock vaccine procurement and represents the global standard for production scale and regulatory compliance.
• Zhongmu Co. (中牧股份): State-owned animal health subsidiary of Sinochem (600195), one of China's largest integrated animal health and nutrition companies. Overlaps with Shen Lian across vaccines, diagnostics, and feed additives, but operates as a much broader conglomerate rather than a focused biologics specialist.

Direct peers

• Tecon Biology (天康生物): Shenzhen-listed integrated animal health and feed company (002100) producing veterinary vaccines (including FMD) for pigs and cattle. Competes directly with Shen Lian in the Chinese livestock vaccine market and operates vertically integrated production.
• Pulike Biological (普莱柯生物): Shanghai-listed veterinary vaccine and diagnostics company (603566) with overlapping product lines in swine vaccines (PCV2, FMD) and a comparable R&D-driven positioning. Pulike's product portfolio and channel footprint overlap substantially with Shen Lian's livestock segment.
• Haili Biological (海利生物): Shanghai-listed animal health company (603718) producing veterinary vaccines and biological products with a focus on livestock. Overlaps with Shen Lian in FMD and swine vaccine categories, representing another mid-tier Chinese competitor in the biologics market.
• Jinyu Biotechnology (金宇生物技术): China's largest veterinary vaccine producer, listed on Shanghai Stock Exchange (600201). Directly competes in FMD, swine, and poultry vaccines with Shen Lian, and operates a much broader and more established distribution network across China. The two companies are the most direct competitors in the synthetic peptide and inactivated FMD vaccine categories.
• Keqian Biological (科前生物): STAR Market-listed veterinary vaccine company (688526) specializing in livestock vaccines, particularly pseudorabies and classical swine fever. Most direct STAR Market peer to Shen Lian, with similar regulatory positioning and target customers (large Chinese pig and livestock farms).
• Winsun Bio (永顺生物): Veterinary vaccine manufacturer listed on Beijing Stock Exchange, with a product portfolio overlapping in livestock vaccines (especially swine). Direct competitor in the Chinese veterinary biologicals category with comparable size and technology profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shen Lian Biomedical